Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

WuXi Biologics Collaborates with I-Mab to Develop Three BiSpecifics

publication date: Sep 26, 2018

WuXi Biologics formed a collaboration with I-Mab Biopharma to develop three bi-specific antibodies, using WuXi's proprietary WuXiBody™ Platform to discover, develop and commercialize the three antibodies. I-Mab will make an unspecified upfront payment to WuXi plus milestones and royalties. WuXi Biologics will be I-Mab's exclusive partner to develop and manufacture the bispecifics. According to WuXi, I-Mab is the first company to use the WuXiBody platform, which it believes improves the development and manufacturing of bi-specifics. More details....

Stock Symbol: (HK: 2269)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.